Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 20Sarcoma 8Breast Neoplasms 5Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Carcinoma, Squamous Cell 3Pancreatic Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Carcinoma, Basal Cell 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sezary Syndrome 1Sarcoma, Kaposi 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Peritoneal Neoplasms 1Paget Disease, Extramammary 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma 1Muir-Torre Syndrome 1Microcystic adnexal carcinoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1

Interventions

trametinib 1talimogene laherparepvec 1spartalizumab 1pembrolizumab 1nazartinib 1exemestane 1canakinumab 1Telomerase 1Tamoxifen 1Surgical Procedures, Operative 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Pemetrexed 1Paclitaxel 1Mastectomy, Subcutaneous 1Mastectomy, Segmental 1Mammaplasty 1Letrozole 1Indocyanine Green 1Doxorubicin 1Docetaxel 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Ductal × talimogene laherparepvec × Clear all
NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡